Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 577 Triple Negative Breast Neoplasms 125 Neoplasm Metastasis 50 Breast Neoplasms, Male 28 Ovarian Neoplasms 26 Neoplasms 26 Inflammatory Breast Neoplasms 22 Carcinoma, Non-Small-Cell Lung 19 Stomach Neoplasms 14 Endometrial Neoplasms 11 Carcinoma, Ductal, Breast 11 Carcinoma, Ovarian Epithelial 10 Pancreatic Neoplasms 9 Colorectal Neoplasms 9 Melanoma 8 Lung Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 HER2-positive Breast Cancer 7 Squamous Cell Carcinoma of Head and Neck 6 Prostatic Neoplasms 6 Esophageal Neoplasms 6 Carcinoma, Renal Cell 6 Uterine Cervical Neoplasms 5 Urinary Bladder Neoplasms 4 Brain Neoplasms 4 Anatomic Stage I Breast Cancer AJCC v8 4 Advanced Breast Cancer 4 Small Cell Lung Carcinoma 3 Sarcoma 3 Recurrence 3

Interventions

Fulvestrant 6 Letrozole 4 Capecitabine 4 exemestane 3 dalpiciclib 3 Trastuzumab 3 Docetaxel 3 Anastrozole 3 ribociclib 2 palbociclib 2 fluzoparib 2 apatinib 2 Irinotecan 2 Gemcitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pyrotinib 1 pegfilgrastim 1 patritumab deruxtecan 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Rogaratinib 1 Patient Reported Outcome Measures 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × Paclitaxel × Breast × Clear all

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡